<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0" xml:base="http://harvardscience.harvard.edu" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
 <title>all David J. Kuter stories</title>
 <link>http://harvardscience.harvard.edu/stories/person/20103</link>
 <description>Stories and external links referencing a person (RSS)</description>
 <language>en</language>
<item>
 <title>Drug based on MGH discovery may significantly improve treatment of dangerous blood disorder </title>
 <link>http://harvardscience.harvard.edu/medicine-health/articles/drug-based-mgh-discovery-may-significantly-improve-treatment-dangerous-bloo</link>
 <description>&lt;!--paging_filter--&gt;&lt;p&gt;Two clinical trials of the novel drug romiplostim (Nplate) show that it significantly improved &lt;a title=&quot;&quot; href=&quot;http://www.fi.edu/learn/heart/blood/platelet.html&quot;&gt;platelet&lt;/a&gt; levels in patients with chronic &lt;a title=&quot;&quot; href=&quot;http://www.nhlbi.nih.gov/health/dci/Diseases/Itp/ITP_WhatIs.html&quot;&gt;immune thrombocytopenic purpura&lt;/a&gt; (ITP), a&amp;nbsp;hematologic disorder that can cause uncontrolled bleeding.&amp;nbsp; An international research team reports Phase 3 trial results for the drug, which duplicates the action of a natural hormone discovered by a &lt;a href=&quot;http://www.massgeneral.org/&quot;&gt;Massachusetts General Hospital&lt;/a&gt; (MGH) investigator, in the February 2 issue of &lt;a title=&quot;&quot; href=&quot;http://www.thelancet.com/&quot;&gt;The Lancet&lt;/a&gt;. &lt;/p&gt;&lt;p&gt;&lt;a href=&quot;http://harvardscience.harvard.edu/medicine-health/articles/drug-based-mgh-discovery-may-significantly-improve-treatment-dangerous-bloo&quot;&gt;read more&lt;/a&gt;&lt;/p&gt;</description>
 <pubDate>Mon, 04 Feb 2008 15:51:43 -0500</pubDate>
 <dc:creator>yvette</dc:creator>
 <guid isPermaLink="false">20088 at http://harvardscience.harvard.edu</guid>
</item>
</channel>
</rss>
